Castration-Resistant Prostate Cancer

P2, N=58, Active, not recruiting, OHSU Knight Cancer Institute | Trial completion date: Jun 2025 --> Jun 2026

P1, N=80, Recruiting, ARTBIO Inc. | Trial completion date: Sep 2033 --> Nov 2028

P=N/A, N=60, Active, not recruiting, Ankara City Hospital Bilkent

The use of PARPis in the treatment of CRPC demonstrated a significant improvement in PFS irrespective of HRR status. Even in the HRR-proficient subpopulation, PARPi-based therapy conferred encouraging PFS benefits, underscoring its potential clinical relevance beyond HRR-deficient settings. Further biomarker analyses are warranted to refine patient selection and optimize therapeutic strategies.

Here, we use long-timescale all-atom molecular dynamics (MD) simulations and nuclear magnetic resonance (NMR) spectroscopy to determine how small molecules stabilize highly dynamic, heterogeneous intermolecular interfaces that mediate oligomerization of the androgen receptor activation domain. The mechanisms determined here explain the relative potencies of androgen receptor activation domain inhibitors and suggest general strategies for designing small molecules that target oligomeric and, potentially, condensed forms of intrinsically disordered proteins.

P1/2, N=180, Not yet recruiting, T.O.A.D. Oncology SA

P1/2, N=148, Active, not recruiting, OncoC4, Inc. | Recruiting --> Active, not recruiting

P2, N=110, Recruiting, Novartis Pharmaceuticals | Trial completion date: Jan 2028 --> Apr 2026

This large real-world study, through the workflow adopted by clinicians for HRR genomic testing, provides novel insights into the variables influencing the success rate of genomic testing.

P1/2, N=73, Not yet recruiting, Radiopharm Theranostics, Ltd

P2, N=22, Recruiting, University of Utah | Trial primary completion date: Dec 2025 --> Dec 2026

[68Ga]Ga-PSMA-11 PET/CT revealed clinically relevant PSMA expression in a subset of mTNBC patients. These results support further investigation of PSMA-targeted RLT in this biomarker-defined population.